CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact

Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CHRNB4 (ImmuneEditome ID:1143)

1. Gene summary of enriched editing regions for CHRNB4

check button Gene summary
Gene informationGene symbol

CHRNB4

Gene ID

1143

GeneSynonyms-
GeneCytomap

15q25.1

GeneTypeprotein-coding
GeneDescriptionneuronal acetylcholine receptor subunit beta-4|acetylcholine receptor, nicotinic, beta 4 (neuronal)|cholinergic receptor, nicotinic, beta 4 (neuronal)|cholinergic receptor, nicotinic, beta polypeptide 4|neuronal nicotinic receptor beta 4 subunit
GeneModificationdate20230329
UniprotIDP30926;H3BU02
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr15:78624465-78624692:-ENST00000261751.6ENSG00000117971.10CHRNB4UTR3L2b,AluSx1chr15:78624465-78624692:-.alignment
chr15:78624465-78624692:-ENST00000412074.5ENSG00000117971.10CHRNB4UTR3L2b,AluSx1chr15:78624465-78624692:-.alignment


Top

2. Tumor-specific enriched editing regions for CHRNB4


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for CHRNB4


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for CHRNB4


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for CHRNB4


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000117971.10,CHRNB4CESCEAGNK_cells_activated5.6532e-030.3858image
chr15:78624465-78624692:-HNSCEERMast_cells_resting3.1995e-02-0.3007image
ENSG00000117971.10,CHRNB4HNSCEAGMast_cells_resting3.1995e-02-0.3007image
ENSG00000117971.10,CHRNB4LUSCEAGMacrophages_M21.7042e-040.4405image
ENSG00000117971.10,CHRNB4OVEAGMonocytes3.7750e-02-0.2667image
ENSG00000117971.10,CHRNB4STADEAGNeutrophils2.4573e-040.6597image


Top

6. Enriched editing regions and immune gene sets for CHRNB4


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000117971.10,CHRNB4ESCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.2368e-03-0.4084image
chr15:78624465-78624692:-HNSCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.2033e-030.4191image
ENSG00000117971.10,CHRNB4HNSCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.2033e-030.4191image
ENSG00000117971.10,CHRNB4OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5857e-02-0.3077image
chr15:78624465-78624692:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER9.7096e-030.2218image
ENSG00000117971.10,CHRNB4PCPGGSVA_HALLMARK_UV_RESPONSE_DNEAG9.8713e-030.2214image
ENSG00000117971.10,CHRNB4STADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG5.9324e-030.5246image
ENSG00000117971.10,CHRNB4TGCTGSVA_HALLMARK_UV_RESPONSE_DNEAG1.9297e-030.3956image


Top

7. Enriched editing regions and drugs for CHRNB4


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000117971.10,CHRNB4ESCAGNF.2EAG6.6769e-030.3788image
chr15:78624465-78624692:-HNSCCI.1040EER1.1640e-03-0.4420image
ENSG00000117971.10,CHRNB4HNSCCI.1040EAG1.1640e-03-0.4420image
ENSG00000117971.10,CHRNB4LUSCBI.D1870EAG4.1407e-030.3434image
ENSG00000117971.10,CHRNB4OVBMS.708163EAG8.1368e-030.3359image
chr15:78624465-78624692:-PCPGDMOGEER2.3790e-02-0.1945image
ENSG00000117971.10,CHRNB4PCPGDMOGEAG2.3993e-02-0.1942image
ENSG00000117971.10,CHRNB4STADAZD6244EAG1.2165e-03-0.5993image
ENSG00000117971.10,CHRNB4TGCTLapatinibEAG6.5216e-04-0.4311image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr15:78624465-78624692:-ENST00000261751.6P30926DB00184NicotineSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB00202SuccinylcholineSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB00237ButabarbitalSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB00472FluoxetineSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB00514DextromethorphanSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB00565CisatracuriumSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB00898EthanolSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB01090PentoliniumSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000261751.6P30926DB01227LevacetylmethadolSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00184NicotineSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00202SuccinylcholineSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00237ButabarbitalSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00472FluoxetineSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00514DextromethorphanSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00565CisatracuriumSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB00898EthanolSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB01090PentoliniumSmallMoleculeDrug
chr15:78624465-78624692:-ENST00000412074.5P30926DB01227LevacetylmethadolSmallMoleculeDrug